Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction
NCT ID: NCT03678467
Last Updated: 2022-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
6 participants
INTERVENTIONAL
2021-03-31
2023-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EVPOME Versus AlloDerm in Subjects Reconstructed With Large Defect Mandibular Resection
NCT01834339
Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management
NCT05664815
The Clinical and Radiographic Outcomes of a 3D-printed Patient-specific Biomimetic Bone Substitute in Maxillofacial Indications: an Interventional, Multi-centred, Open-label, Post-market Clinical Investigation.
NCT04773847
Bone Regeneration With Mesenchymal Stem Cells
NCT02755922
Regeneration of Alveolar Sockets With rhBMP-2-loaded Bovine Bone Mineral
NCT05717478
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EB-CMF Implant
Subject receiving EB-CMF implant
EB-CMF
Autologous, anatomically shaped bone graft
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EB-CMF
Autologous, anatomically shaped bone graft
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Stable mandibular ramus injury or defect due to trauma, disease, or congenital defects.
3. Medical history must be verified by either a personal physician or medical practitioner as appropriate.
4. Patient determined by the Investigator to be a suitable candidate by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac evaluation.
5. A female patient is eligible to participate if she is not pregnant (see Appendix 6), not breastfeeding, and at least 1 of the following conditions applies:
1. A woman of nonchildbearing potential (WONCBP) as defined in Appendix 6. OR
2. A woman of childbearing potential (WOCBP) who agrees to follow the contraceptive guidance in Appendix 6 for at least 1 month prior to surgery, during the treatment period, and until 12 weeks after completion of the study.
6. Patient must be available at the study center for all specified assessments throughout the study duration.
7. Patients whose clinical laboratory test results are within the reference range for healthy individuals, or where outside the reference range is judged as not clinically relevant by the Investigator.
8. All patients are required to give written informed consent as described in Appendix 2, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, and in accordance with the Declaration of Helsinki, before enrollment. Patients must provide written informed consent and authorization for use and disclosure of protected health information.
9. A healthy condyle which can be plated with titanium plates and screws.
10. A mandibular continuity ramus defect which starts below the sigmoid notch and extends only as far as but not including the angle.
Exclusion Criteria
2. Mandibular ramus defects with open wounds.
3. Defects \> 15 cc in volume.
4. Defects \> 6 cm in diameter.
5. Systemic disease that would render the fat harvest and product implantation, along with associated anesthesia, unsafe to the patient.
6. Patient has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would impact patient safety or interfere with the integrity of the study data.
7. Active uncontrolled infection or malignancy. Patients will be allowed to undergo rescreening once, after the infection is cleared, if they are willing to do so.
8. Patients with signs and symptoms of infection between Screening and up to the surgical implantation.
9. Radiation therapy \< 6 months prior to the surgical implantation.
10. Need for soft tissue reconstruction (flap, skin graft, etc).
11. Conditions that may impact the success of the surgical implantation or increase the risk of postoperative complications, including inherited coagulopathies like hemophilia, Von Willebrand's disease, protein C and S deficiency, thrombocythemias, thallassemias, sickle cell disease, etc.
12. Conditions that may impact functional outcomes, including uncontrolled diabetes, osteoporosis, rare disorders of bone healing like osteopetrosis, or any other metabolic bone disease.
13. Increased alkaline phosphatase (to exclude Paget's disease), increased serum calcium (to exclude hyperparathyroidism), or Vitamin D deficiency, at Screening, confirmed by a repeat test.
14. Oral bisphosphonate \< 12 weeks, intravenous bisphosphonate \< 12 months prior to Screening or use of systemic steroids or anabolic agents (e.g. teriparatide) for osteoporosis treatment.
15. Patients with inadequate donor sites for lipoaspirate of adipose tissue.
16. Mixed connective tissue diseases and collagen diseases which can result in poor wound healing after surgery.
17. Patients considered unsuitable per the consulted surgeon.
18. Patient has any of the following conditions as identified by medical history:
1. Human immunodeficiency virus (active or seropositive).
2. Active tuberculosis.
3. Active hepatitis B infection.
4. Hepatitis C.
5. Viral encephalitis.
6. Toxoplasmosis. In case of doubt regarding mentioned conditions based on the physical examination or other signs or symptoms present at Screening, the patient will be asked to consent to additional testing to rule out such conditions or the patient must be excluded from the study.
19. Donation of blood and blood products is not permitted from Screening and for at least 3 months after the surgical implantation.
20. Patient participated in another clinical study of an investigational drug within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the surgical implantation or is currently participating in another clinical study of an investigational drug or intending to participate in another clinical study of an investigational drug before completion of all scheduled evaluations in this clinical study.
21. Patients who, in the opinion of the Investigator, are not likely to complete the study for whatever reason.
22. The Investigator or any sub-investigator, research assistant, surgeon, study coordinator, or other staff directly involved in the conduct of the clinical study or any of their relatives.
23. Hypersensitivity to any product of bovine origin.
24. Hypersensitivity to gentamicin or other aminoglycosides.
25. Post-menopausal women who have an abnormally low bone mineral density or have not tested for bone mineral density.
26. Patients with discontinuity defects of the ramus.
27. Patients with a history of malignant cancer.
28. Hypersensitivity or allergy to epinephrine or other drugs commonly used during surgery.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Epibone, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian R Gastman, MD
Role: PRINCIPAL_INVESTIGATOR
The Cleveland Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Healthcare System, San Francisco
San Francisco, California, United States
Cleveland Clinic
Cleveland, Ohio, United States
UT Health San Antonio
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Rebeka Silva, DMD, FACD
Role: primary
Beverly Doyle
Role: primary
Erin Locke, BSN, RN
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Bhumiratana S, Bernhard JC, Alfi DM, Yeager K, Eton RE, Bova J, Shah F, Gimble JM, Lopez MJ, Eisig SB, Vunjak-Novakovic G. Tissue-engineered autologous grafts for facial bone reconstruction. Sci Transl Med. 2016 Jun 15;8(343):343ra83. doi: 10.1126/scitranslmed.aad5904.
Bhumiratana S, Vunjak-Novakovic G. Concise review: personalized human bone grafts for reconstructing head and face. Stem Cells Transl Med. 2012 Jan;1(1):64-9. doi: 10.5966/sctm.2011-0020. Epub 2011 Dec 7.
Grayson WL, Marolt D, Bhumiratana S, Frohlich M, Guo XE, Vunjak-Novakovic G. Optimizing the medium perfusion rate in bone tissue engineering bioreactors. Biotechnol Bioeng. 2011 May;108(5):1159-70. doi: 10.1002/bit.23024. Epub 2010 Dec 22.
Grayson WL, Bhumiratana S, Cannizzaro C, Vunjak-Novakovic G. Bioreactor cultivation of functional bone grafts. Methods Mol Biol. 2011;698:231-41. doi: 10.1007/978-1-60761-999-4_18.
Related Links
Access external resources that provide additional context or updates about the study.
EpiBone, Inc.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EB-CMF-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.